FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
Top News Most Read Highlighted
Get Alerts ABBV Hot Sheet
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend: Up
Today’s Overall Ratings:
Up: 30 | Down: 43 | New: 39
Earlier, UBS initiated coverage on Abbvie (NYSE: ABBV) with a Neutral rating and $36 price target.
The firm comments, “Our thesis is three-fold: (1) Humira should be durable but competition from oral therapies and generics for now will remain a concern for investors. (2) Earnings in 2013/2014 will be held down by ~$2.5-3B sales hit from its lipid and HIV franchises going generic. (3) The late stage pipeline doesn’t kick in until 2015-16 and it’s still unclear how big its most important asset, the HCV franchise, will be given how quickly market dynamics are changing.”
EPS estimates are $3.08 for 2013 and $3.20 for 2014. 5 year CAGRs are 1% for revenues and 2% for EPS.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $34.00 yesterday, with a 52 week range of $33.33-$35.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW